The Prague Post - Pfizer-BioNTech begin Omicron vaccine trial

EUR -
AED 4.28433
AFN 80.750534
ALL 97.456108
AMD 448.076257
ANG 2.087576
AOA 1069.624325
ARS 1491.806663
AUD 1.781558
AWG 2.100174
AZN 1.987156
BAM 1.950723
BBD 2.355171
BDT 141.142668
BGN 1.95441
BHD 0.439751
BIF 3371.592727
BMD 1.166439
BND 1.493925
BOB 8.089017
BRL 6.50092
BSD 1.166464
BTN 100.221028
BWP 15.563628
BYN 3.817398
BYR 22862.209806
BZD 2.343122
CAD 1.598623
CDF 3366.344096
CHF 0.930958
CLF 0.029439
CLP 1129.665265
CNY 8.360162
CNH 8.365749
COP 4678.587935
CRC 588.772733
CUC 1.166439
CUP 30.910641
CVE 110.811442
CZK 24.678943
DJF 207.299725
DKK 7.46387
DOP 70.329186
DZD 151.420431
EGP 57.688241
ERN 17.496589
ETB 159.666793
FJD 2.623614
FKP 0.862062
GBP 0.868356
GEL 3.161155
GGP 0.862062
GHS 12.122978
GIP 0.862062
GMD 83.397702
GNF 10096.69833
GTQ 8.960679
GYD 243.947205
HKD 9.156496
HNL 30.735461
HRK 7.53601
HTG 153.101545
HUF 399.961512
IDR 18983.68257
ILS 3.910143
IMP 0.862062
INR 100.3125
IQD 1528.035451
IRR 49121.67341
ISK 142.399108
JEP 0.862062
JMD 186.872053
JOD 0.826958
JPY 172.299408
KES 151.056106
KGS 102.001152
KHR 4690.252436
KMF 492.528911
KPW 1049.795538
KRW 1612.99875
KWD 0.356394
KYD 0.972078
KZT 612.092243
LAK 25119.269841
LBP 104454.637468
LKR 350.956616
LRD 234.454498
LSL 20.902345
LTL 3.444192
LVL 0.705567
LYD 6.292921
MAD 10.500873
MDL 19.759744
MGA 5167.326179
MKD 61.45538
MMK 2449.521793
MNT 4180.757141
MOP 9.431535
MRU 46.30903
MUR 53.015073
MVR 17.97086
MWK 2025.515401
MXN 21.84301
MYR 4.96028
MZN 74.605452
NAD 20.901934
NGN 1780.733183
NIO 42.866693
NOK 11.832914
NPR 160.354044
NZD 1.952363
OMR 0.448512
PAB 1.166474
PEN 4.136778
PGK 4.811489
PHP 66.092716
PKR 331.706188
PLN 4.255812
PYG 9036.482044
QAR 4.24654
RON 5.078093
RSD 117.161872
RUB 91.094653
RWF 1672.673921
SAR 4.37482
SBD 9.712342
SCR 16.795014
SDG 700.43179
SEK 11.215378
SGD 1.495638
SHP 0.916638
SLE 26.262838
SLL 24459.652997
SOS 666.619652
SRD 43.397961
STD 24142.937977
SVC 10.206437
SYP 15166.02623
SZL 20.902252
THB 37.897422
TJS 11.262186
TMT 4.094202
TND 3.386152
TOP 2.731917
TRY 46.871426
TTD 7.917462
TWD 34.260678
TZS 3023.237929
UAH 48.780627
UGX 4180.120999
USD 1.166439
UYU 47.406622
UZS 14761.289259
VES 133.28729
VND 30473.22608
VUV 139.561149
WST 3.039166
XAF 654.259861
XAG 0.03044
XAU 0.000348
XCD 3.152361
XDR 0.81363
XOF 653.791259
XPF 119.331742
YER 282.103061
ZAR 20.88828
ZMK 10499.330322
ZMW 27.061802
ZWL 375.592971
  • CMSC

    0.0900

    22.314

    +0.4%

  • CMSD

    0.0250

    22.285

    +0.11%

  • RBGPF

    0.0000

    69.04

    0%

  • SCS

    0.0400

    10.74

    +0.37%

  • RELX

    0.0300

    53

    +0.06%

  • RIO

    -0.1400

    59.33

    -0.24%

  • GSK

    0.1300

    41.45

    +0.31%

  • NGG

    0.2700

    71.48

    +0.38%

  • BP

    0.1750

    30.4

    +0.58%

  • BTI

    0.7150

    48.215

    +1.48%

  • BCC

    0.7900

    91.02

    +0.87%

  • JRI

    0.0200

    13.13

    +0.15%

  • VOD

    0.0100

    9.85

    +0.1%

  • BCE

    -0.0600

    22.445

    -0.27%

  • RYCEF

    0.1000

    12

    +0.83%

  • AZN

    -0.1200

    73.71

    -0.16%

Pfizer-BioNTech begin Omicron vaccine trial
Pfizer-BioNTech begin Omicron vaccine trial

Pfizer-BioNTech begin Omicron vaccine trial

Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.

Text size:

Pfizer's CEO Albert Bourla has previously said that the pharmaceutical giant could be ready to file for regulatory approval of the shot by March.

The company's head of vaccine research Kathrin Jansen said in a statement that while current data showed that boosters against the original Covid strain continued to protect against severe outcomes with Omicron, the company was acting out of caution.

"We recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," she said.

Ugur Sahin, CEO of the German biotech company BioNTech added that the protection of the original vaccine against mild and moderate Covid appeared to wane more rapidly against Omicron.

"This study is part of our science-based approach to develop a variant-based vaccine that achieves a similar level of protection against Omicron as it did with earlier variants but longer duration of protection."

The trial will involve 1,420 people aged 18-55.

A spokesperson for Pfizer said that it did not include people older than 55 because the goal of the study was to examine the immune response of participants dosed, rather than estimate vaccine efficacy.

The trial is taking place across the United States and South Africa, and the first participant was dosed in North Carolina.

The volunteers are split into three groups.

The first involves people who previously received two doses of the current Pfizer-BioNTech vaccine 90-180 days prior to enrollment, and will receive one or two doses of the Omicron vaccine.

The second will be people who got three doses of the current vaccine 90-180 days prior to the study and will receive either another dose of the original shot or an Omicron-specific vaccine.

The third and final group are people who have never previously received a Covid vaccine, and will receive three doses of the Omicron-specific vaccine.

The Pfizer-BioNTech vaccine was the first Covid shot to be authorized in the West, in December 2020.

Because it is based on messenger RNA technology, it is relatively easy to update to reflect the genetic code of new variants.

Several countries have begun to emerge from their latest waves driven by Omicron, the most transmissible strain to date, even though global new cases are still rising.

The coronavirus has killed some 5.6 million people since the outbreak emerged in China in December 2019.

M.Jelinek--TPP